Evidence map›Paper›PMID 35756970›Full record

ReviewImmuno-oncology technology2021

The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens.

D W Vredevoogd, G Apriamashvili, D S Peeper

Open access · goldAbstract readReview
In one paragraph

Review in Immuno-oncology technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

D W VredevoogdNetherlands Cancer Institute, Oncode Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands.
G ApriamashviliNetherlands Cancer Institute, Oncode Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands.
D S PeeperNetherlands Cancer Institute, Oncode Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands.
Oncode Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Functional genetic screens by CRISPR-Cas9 allow for the unbiased discovery of proteins causally involved in complex biological processes. In recent years, this approach has been used by multiple laboratories to uncover a range of tumor cell regulators determining immune sensitivity. In this review, we provide an overview of genetic screens carried out both

Indexed as

CRISPR-Cas9genetic screenimmune checkpoint blockadeimmunotherapytherapy resistance

Identifiers

PMID35756970
PMCPMC9216628
OpenAlexW3208604899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.